Skip to content
Open access

The value of terahertz three-dimensional tomography for the differential diagnosis of tumor tissue and normal tissue in lung cancer nude mice

Sep 2026 · Frontiers in Bioengineering and Biotechnology · Vol 14 · 0 citations · 34 references
Medicine

TL;DR

Findings support proof-of-concept signal enhancement in a subcutaneous xenograft model but do not establish a clinical tumor-to-normal-lung contrast ratio.

Abstract

Introduction To investigate the value of terahertz (THz) spectroscopy combined with gold nanorods (GNRs) in the differential diagnosis of lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Methods Tumor-bearing nude mouse models were established using GNR-treated A549 (LUAD) and NCI-H520 (LUSC) cells. Reflective THz 3D imaging and transmission THz time-domain spectroscopy (THz-TDS) systems, together with CT imaging and pathological validation, were employed to analyze the THz spectral characteristics of in vivo tumors, paraffin-embedded tissues, and thin sections. Results CCK-8 and live/dead staining supported the biocompatibility of 40 μg/mL GNRs under the tested conditions. In vivo THz imaging showed higher tumor-region signals in the GNR-treated groups. At 0.5 THz, the model-specific tumor-to-adjacent skin/subcutaneous ROI contrast ratio in the LUSC group was 36:1 after GNR treatment and 22:1 in the untreated control; The contrast ratio of the GNR-treated LUSC group is 25:1, while that of the untreated control group is 19:1. Among the tested frequency bands, 0.5 THz provided the clearest image contrast. Contrast decreased markedly in paraffin-embedded tissues (approximately 2:1), and spectral differences in routine 5 μm human sections were obscured by the glass substrate. These findings support proof-of-concept signal enhancement in a subcutaneous xenograft model but do not establish a clinical tumor-to-normal-lung contrast ratio. Discussion Under the tested conditions, GNR treatment was associated with higher THz signals in subcutaneous LUSC and LUAD xenografts. The mechanism and clinical performance remain unestablished; the approach should be regarded as proof-of-concept and as a potential complement to, rather than a replacement for, standard histopathology.

Read PDF

Similar papers

Conference Oct 2026

Feasibility study of multispectral imaging guided Raman spectroscopy for breast cancer diagnosis

Accurate breast cancer diagnosis on fresh surgical specimens requires an optical workflow that can first localize diagnostically relevant tissue regions and then verify these regions using molecular information. In this feasibility study, multispectral imaging (MSI) was used to delineate regions of interest (ROIs) on f...

Qian Chen, Jian-Feng Wang, Shu-Yu Chen et al. · 0 citations
Open access Oct 2026

PET/CT with Gold Nanoparticle Contrast Enhancement as a Method for Evaluating the Anatomical and Physiological Parameters of B16F10 Melanoma Tumor Model

Introduction : Hybrid positron emission tomography and computed tomography (PET/CT) is widely used in experimental oncology; however, on native CT images, tumor tissue is indistinguishable from normal soft tissues. Contrast agents based on gold nanoparticles (AuNPs) have been proposed to address this issue. Pur...

Y. Finogenova, V. Skribitsky, K. Shpakova et al. · 0 citations
Open access 2026

PD-L1-targeted dual-modal MR/NIR-II probe for imaging and image-guided surgery of non-small cell lung cancer

Recurrence of non-small cell lung cancer remains a critical clinical challenge. Primarily due to undetectable micrometastatic lesions and incomplete tumor resection. Current preoperative imaging modalities lack sufficient resolution to identify small lesions, while intraoperative guidance relies on visual inspection or...

Qing-Yun Liu, Xiao-Hua Jia, Yu-Tao Li et al. · 0 citations
Open access Jan 2026

High‐Resolution Imaging via UHF‐US–Based 3D Reconstruction in a 3D In Vivo Tumor Model

The chorioallantoic membrane (CAM) model resembles a preclinical in vivo platform for the engraftment of different tumors and is especially well‐suited for the development and evaluation of novel cancer therapies. Due to the CAM′s extensive vascular network, it can sustain engrafted human tumor tissue, which can be use...

A. Ettner-Sitter, Jonas Kuenzel, Mia Heidenreich et al. · 0 citations
Open access Oct 2026

Quad-Band Terahertz Metamaterial Sensor Based on Dual Near-Perfect Absorption for Fingerprint Identification of Cancer Cells

Early and accurate cancer diagnosis remains a critical challenge in clinical oncology due to the limitations of traditional, destructive labeling methods. To address this gap, this study proposes a novel, label-free quad-band terahertz (THz) metamaterial biosensor designed for high-precision fingerprint identification...

Aykut Coşkun, A. Özmen · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.